

INTRODUCTION

The publication of AfroCentric's results for the year ended June 30, 2014 coincides with the announcement of two important strategic initiatives for AfroCentric which are briefly explained herein under "Recent Developments".

- an agreement to acquire WAD Holdings Proprietary Limited ("WAD") businesses that specialise in wholesaling, dispensing and delivery of chronic medication; and
- an agreement for a significant minority investment by Sanlam Limited.

During fiscal 2014 certain material corporate events occurred. These include the final measurement of the three year profit warranty provided by AfroCentric Health Limited, the second tranche payment share issue as a result of the warranty attainment, as well as shares issued on the redemption of the AfroCentric Preference Shares. Consideration of these events will provide shareholders with a better appreciation of the Group's performance.

- Solid financial performance
- 47% ↑ in headline earnings
- 20% ↑ in dividend
- Acquisition of WAD pharmaceutical logistics businesses
- Significant minority investment by SANLAM

SALIENT FEATURES

	Audited year ended 30/6/2014	Audited year ended 30/6/2013
Basic earnings (rands)	153.8 million	163.6 million
Headline earnings (rands)	183.9 million	129.6 million
Diluted earnings (cents per share)	40.00	36.11
Diluted headline earnings (cents per share)	47.83	28.62
Basic earnings (cents per share)	40.00	60.75
Headline earnings (cents per share)	47.83	48.15

RECENT DEVELOPMENTS

AfroCentric has been under a Cautionary notice since 10 June 2014. The Board is now pleased to announce that the Company has concluded two material transactions, the broad nature of which are as follows:

1. Agreement has been reached to acquire the wholesale and courier pharmacy businesses belonging to WAD Holdings (Proprietary) Limited ("WAD"), businesses that specialise in the wholesaling, dispensing and delivery of chronic medication for and on behalf of private and public sector clients and patients. In addition, the transaction will include the purchase of the group's agency enterprise and a strategic minority interest in the generic and OTC complementary medicine distribution business. The Company has also secured an option to acquire WAD's two specialised commercial properties. The purchase price will be satisfied substantially by the issue of AfroCentric shares and a certain amount in cash.
2. Agreement has been reached with Sanlam Limited ("SANLAM"), whereby SANLAM will acquire a 28.7% shareholding in ACT Healthcare Assets (Proprietary) Limited ("AHA"), a wholly owned subsidiary of AfroCentric which owns 94.10% of AfroCentric Health Limited ("AHL"). The total SANLAM investment amount will be approximately R700 million (after the transfer of acquired WAD businesses referred to above) of which about R160 million will be applied to the repayment of AHA third party borrowings, the balance being applied to the repayment of inter-company loans between AHA and the Company. As a result of the total SANLAM investment, and the repayment of third party debt of approximately R160 million, AfroCentric shall be substantially debt-free and have additional cash

resources of approximately R542 million. The SANLAM Investment is subject to certain suspensive conditions being fulfilled or waived.

Further information and details of the transactions were released on SENS on 30 September 2014.

PROSPECTS

Apart from the Group's consistent past trends of growth, both transactions referred to herein, expand the Group's value proposition for all stakeholders, materially enhances its marketing and distribution channels, significantly expands its capital base and positively positions the Group for accelerated growth.

FULL ANNOUNCEMENT

The contents of this short form announcement are the responsibility of the Board of Directors. Shareholders are advised that this short form announcement represents a summary of the information contained in the full announcement, published on the Stock Exchange News Service (SENS) and on AfroCentric's website (www.afrocentric.za.com) on 30 September 2014.

Any investment decisions should be made based on consideration of the full announcement and audited annual financial statements which are available for inspection at the registered offices of the Company.

On behalf of the Board




Dr A Mokgokong
Chairperson

D Dempers
Group Chief Executive Officer

DIVIDEND DECLARATION

The Board of Directors has pleasure in announcing that a dividend of 18 cents per ordinary share (gross) has been declared for the year ended 30 June 2014. Dividends are subject to Dividends Withholding Tax. The payment date for the dividend is 1 December 2014. For further details on the dividend declaration, refer to the full announcement on AfroCentric's website (www.afrocentric.za.com)

FINANCIAL HIGHLIGHTS



By Order of the Board

Wilbert Mhlanga
Company secretary
Johannesburg
1 October 2014

Directors

AT Mokgokong** (Chairperson), D Dempers (CEO)***, WRC Holmes (CFO)***, NB Bam**, JM Kahn**, MJ Madungandaba**, Y Masithela*, G Napier*, J Appelgryn*, MI Sacks**

*independent non-executive **non-executive ***executive

Registered Office

37 Conrad Rd
Florida North 1709

Sponsor

Sasfin Capital (A division of Sasfin Bank Limited)

AfroCentric Investment Corporation Limited

Incorporated in the Republic of South Africa
Registration number 1988/000570/06
JSE Code: ACT
ISIN: ZAE 000078416
("AfroCentric" or "the Company" or "the Group")